Omaha World-Herald (Friday, September 14, 2018): Experimental drug ‘nothing short of miraculous’ for father of 4 with super-rare brain tumor Please find the full article here.
Brain Tumor News Blast Issue 5,656 (Wednesday, April 4, 2018): ONC201 is an experimental, orally bioavailable, first-in-class small molecule with demonstrated antitumor activity in preclinical models of difficult-to-treat solid and liquid tumors without imparting significant toxicity. It is currently investigated for its safety and efficacy in the following clinical trials: 1) ONC-201 for Recurrent Glioblastomas
Business Development